Illumina, Inc. (ILMN) Director Sells $1,031,250.00 in Stock
Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction that occurred on Wednesday, November 14th. The shares were sold at an average price of $312.50, for a total value of $1,031,250.00. Following the transaction, the director now owns 376,710 shares of the company’s stock, valued at approximately $117,721,875. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of Illumina stock opened at $319.93 on Monday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. The firm has a market cap of $47.03 billion, a price-to-earnings ratio of 79.98, a price-to-earnings-growth ratio of 2.37 and a beta of 1.07. Illumina, Inc. has a 1-year low of $207.51 and a 1-year high of $372.61.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.26. The firm had revenue of $853.00 million for the quarter, compared to the consensus estimate of $825.65 million. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The firm’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.11 EPS. On average, research analysts forecast that Illumina, Inc. will post 5.75 EPS for the current fiscal year.
A number of research analysts recently issued reports on ILMN shares. UBS Group started coverage on Illumina in a research report on Tuesday, October 9th. They set a “neutral” rating and a $340.00 price objective for the company. Zacks Investment Research lowered Illumina from a “hold” rating to a “sell” rating in a research report on Tuesday, October 16th. Argus set a $372.00 price objective on Illumina and gave the company a “buy” rating in a research report on Friday, August 10th. Piper Jaffray Companies boosted their price objective on Illumina to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, October 2nd. Finally, BidaskClub lowered Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $330.94.
TRADEMARK VIOLATION NOTICE: “Illumina, Inc. (ILMN) Director Sells $1,031,250.00 in Stock” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/11/19/illumina-inc-ilmn-director-sells-1031250-00-in-stock.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Featured Article: Compound Interest
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.